1. Move DMD Trial Update

    Posted on January 31, 201710:58 pm

      The MoveDMD trial with edasalonexent (CAT-1004) in Duchenne muscular dystrophy (DMD) has just completed Part B, and Catabasis has released the top-line results.   Summary: The top-line results that we are reporting are for Part B of a 3-part study in young boys with DMD. Positive results were reported for Part A in 2016. Read more »

  2. Action Alert: Contact Your Texas State Senator Today

    Posted on January 30, 20174:48 pm

      Calling all Texans.  Take action today and let your voices be heard.  Call your Texas State Senator and ask them to support Medicaid funding for the treatment of Duchenne. Overview The Texas Legislative Budget Board (LBB) is made up of a panel of state legislators who must approve all new Medicaid expenditures above $500,000 Read more »

  3. Physical Therapist Darcy Peach Provides Peace of Mind to Duchenne Families

    Posted on January 26, 20173:51 pm

      Darcy Peach discovered her calling to become a physical therapist while undergoing treatment for a volleyball injury in high school. During her treatment sessions, Darcy’s physical therapist took a great deal of care and time in treating her.  She witnessed first-hand the therapeutic and relationship building benefits that occur during the process of physical Read more »

  4. Deflazacort Transition Program Reminder

    Posted on January 17, 20176:42 pm

      Marathon submitted New Drug Applications (NDAs) to the Food and Drug Administration (FDA) last June for deflazacort. The NDAs have been accepted for filing and review. The FDA expects to complete its review of the applications in early February. If approved, deflazacort will become accessible in the U.S. and it would be the second Read more »